A novel therapeutic anti-HBV antibody with increased binding to human FcRn improves in vivo PK in mice and monkeys

Protein Cell. 2018 Jan;9(1):130-134. doi: 10.1007/s13238-017-0438-y.

Ciming Kang¹, Lin Xia^{1

2}, Yuanzhi Chen¹, Tianying Zhang¹, Yiwen Wang¹, Bing Zhou¹, Min You¹, Quan Yuan¹, Chi-Meng Tzeng², Zhiqiang An^{1

3}, Wenxin Luo⁴, Ningshao Xia¹

¹ State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, School of Life Science, Xiamen University, Xiamen, 361105, China.
² Key Laboratory for Cancer T-Cell Theranostics and Clinical Translation (CTCTCT), Translational Medicine Research Center, School of Pharmaceutical Science, Xiamen University, Xiamen, 361105, China.
³ Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
⁴ State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, School of Life Science, Xiamen University, Xiamen, 361105, China. wxluo@xmu.edu.cn.

No abstract available

Publication types